OBJECTIVE: Overexpression of the human transcription factor FOXC2 gene (FOXC2) protects against insulin resistance in mice and a common FOXC2 polymorphism (À512C4T) has been suggested to be associated with insulin resistance in humans. Here, we addressed the potential role for FOXC2 as a candidate gene for type 2 diabetes and associated phenotypes. MATERIALS AND METHODS: A case-control study was performed in 390 type 2 diabetic patients and 307 control subjects. The number of patients was increased to a total of 768 subjects for further study of phenotypic differences relating to the dysmetabolic syndrome relative to genetic variation. The FOXC2 -512C4T polymorphism was genotyped by a restriction fragment length polymorphism PCR assay. RESULTS: FOXC2 À512C4T allele and genotype distribution did not differ between patients with type 2 diabetes and control subjects, but the C/C genotype was associated with increased body mass index (BMI, kg/m 2 ) (P a ¼ 0.03) among type 2 diabetic patients. The FOXC2 -512C4T polymorphism was a significant independent predictor of BMI (P ¼ 0.001) in a multiple regression model including age, gender and affection status. We found no significant association with type 2 diabetes-related metabolic parameters but that the C-allele (P ¼ 0.01) and C/C and C/T genotypes (P ¼ 0.03) were significantly over-represented in type 2 diabetic males with a concomitant diagnosis of dysmetabolic syndrome. CONCLUSION: We conclude that FOXC2 is associated with obesity and metabolic deterioration but does not contribute to an increased risk for type 2 diabetes.
Introduction
Along with the genes encoding PPAR-g, 1 in white adipose tissue exhibit increased insulin sensitivity, lower plasma glucose, insulin and triglyceride levels and appear relatively resistant to diet-induced insulin resistance and obesity. 6 In humans, FOXC2 is expressed in both adipose tissue and skeletal muscle. The expression is sensitive to regulation by insulin and there is an inverse correlation between the levels of FOXC2 mRNA in both visceral fat and muscle and measures of insulin resistance. 7 The T/T genotype of a common polymorphism in the 5 0 untranslated region (5 0 UTR) of the gene (À512C4T) has been associated with increased mRNA expression in visceral compared to subcutaneous fat, and the T-allele with higher insulin sensitivity and lower triglyceride levels. 7, 8 Although these data identified FOXC2 as a candidate gene for insulin resistance and/or type 2 diabetes, three recent reports in Japanese, Pima Indians and Danish Caucasians have failed to identify an association between FOXC2 and type 2 diabetes. [8] [9] [10] In addition, contrasting with previous data, the Tallele was weakly associated with increased waist-to-hip ratio (WHR), plasma triglycerides and measures of insulin resistance in the Danish study. 10 Insulin resistance and additional features of the metabolic, or rather dysmetabolic, syndrome including abdominal obesity, hypertension and dyslipidemia are under strong genetic influence and cluster in families and they are the hallmark feature of type 2 diabetes. 11 A concomitant diagnosis of dysmetabolic syndrome is present in up to 80% of type 2 diabetic patients and is associated with a doubling of the risk for cardiovascular morbidity and mortality. 12 To address the question whether FOXC2 is associated with type 2 diabetes or associated phenotypes, we performed a case-control study in Scandinavian patients with type 2 diabetes and nondiabetic control subjects without a family history of type 2 diabetes. The type 2 diabetic study material was extended and stratified for the number of dysmetabolic syndrome components for a more precise investigation of association to these features.
Materials and methods

Subjects
A case-control association study was performed in a random sample of 390 unrelated type 2 diabetic patients from Finland, one patient per family in the previously published Botnia study 13 and 307 nondiabetic spouses without a family history of type 2 diabetes (age 40 y or older with normal glucose tolerance assessed by a standard oral glucose tolerance test (75 g D-glucose)) to obtain an estimate of allele and genotype frequencies of the 5 0 UTR FOXC2 À512C4T polymorphism and to study its potential role for phenotypes associated with type 2 diabetes. The groups were selected as to match for gender and age. To further investigate the association between FOXC2 À512C4T and type 2 diabetesrelated phenotypes clustering in the dysmetabolic syndrome, another random sample of 378 unrelated patients from both Finland and the South of Sweden was added to the study, amounting to a total number of 768 type 2 diabetic subjects. All subjects gave written informed consent and the study was conducted in accordance with the Declaration of Helsinki and approved by the local University ethics committee.
Case-control association study
The following phenotypes were compared: age (y), total body weight (kg), body mass index (BMI, kg/m 2 ), body fat mass (kg), lean body mass (kg), WHR, fasting plasma glucose (fP-Glucose, mmol/l), fasting serum insulin (fS-Insulin, mU/ ml), homeostasis model assessment insulin resistance index (HOMA-IR), 14 fasting plasma triglycerides (fP-TG, mmol/l) and fasting plasma HDL cholesterol (fP-HDL; mmol/l). In all, 13 of the type 2 diabetic patients (3.3%) and none of the control subjects were treated with antihyperlipidemic agents. The mean duration of type 2 diabetes at the time for phenotypic characterization was 6.3 (2.4-13.1) y in this population.
Stratification for the dysmetabolic syndrome Sufficient data from a total of 768 type 2 diabetic subjects were available from 727 subjects (344 males and 383 females, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] y in this extended population. Since insulin resistance in a control population is defined as the lowest quartile of measures of insulin sensitivity or highest quartile of fasting insulin or HOMA-IR index, the number of insulin-resistant control subjects was too low (n ¼ 77) to allow for a meaningful analysis with enough power to identify differences in allele or genotype distribution, and was therefore not included (data not shown).
Phenotypic characterization
All laboratory specimens were obtained after a 12 h overnight fast. Fasting concentrations of glucose, insulin and lipids were measured as described previously. 13 The HOMA-IR index (fS-Insulin multiplied by fP-Glucose divided by 22.5) was used to estimate the degree of insulin resistance.
14 Body weight, height, waist (measured with a soft tape midway between the lowest rib and the iliac crest), hip circumference (at the widest part of the gluteal region) and body composition by bioimpedance were measured with subjects in light clothing without shoes and BMI and WHR calculated accordingly. Blood pressure was measured (mean of at least two measures) in the supine position after a 10-min rest using a standard forearm manometer. Type 2 diabetes was diagnosed according to the WHO criteria from 1998 16 or by a previous diagnosis of diabetes and treatment with oral agents and/or insulin.
Genotyping DNA was extracted from blood using a conventional method. 17 The FOXC2 À512C4T region was amplified with FOXC2, type 2 diabetes and the dysmetabolic syndrome E Carlsson et al primers 5 0 -GTC TTA GAG CCG ACG GAT TCC TG-3 0 and 5 0 -TGG GGA CCA AGG TGG ACC CTC G-3 0 . PCR was carried out in a 20 ml volume containing 10 mM of each dNTP, 1.5 mM MgCl 2 , 5% DMSO, 0.5 U Taq polymerase (Amersham Pharmacia Biotech, Piscataway, NJ, USA), 10 pmol of each primer and 25 ng genomic DNA. The cycling conditions were 941C for 5 min, 35 cycles of 941C for 30 s, 631C for 30 s and 721C for 30 s, followed by a final extension at 721C for 10 min. PCR products were digested with BbsI (New England Biolabs, Beverly, MA, USA) in 371C overnight. The digested products were separated on 3% agarose gel.
Statistical analyses
Allele and genotype frequencies were compared by w 2 statistics. Continuous variables were compared by nonparametric Kruskal-Wallis one-way ANOVA unless exhibiting normal distribution. Unless predefined by previous data or hypothesis, further tests on differences concerning major variables for the phenotypes (BMI and HOMA-IR) between pooled groups of different genotype carriers were only performed when a significant difference between the groups was found by the initial ANOVA. This may be overly conservative since it does not fully allow us to test for a recessive effect. On the other hand, a significant difference in one group (control subjects or type 2 diabetic patients) was followed up by the reciprocal analysis in the other. Data are presented as median with interquartile range (25-75th percentile). Where applicable, data were adjusted for age and gender (weight, BMI, body fat mass, lean body mass and WHR), or age, gender and BMI (fP-Glucose, HbA 1C , fSInsulin, HOMA-IR, fP-HDL-cholesterol and fP-TG) using the general linear model. Adjusted P-values (P a ) are presented along with unadjusted values. A P-value below 0.05 was considered statistically significant. Since only two major and highly interrelated phenotypic traits were investigated, body composition and insulin resistance, two-tailed P-values are reported without correction for multiple testing. All statistical operations were performed using the Number Cruncher Statistical Software (NCSS, Kaysville, USA).
Results
Clinical characteristics of the study subjects are summarized in Table 1 and allele and genotype frequencies for the FOXC2 -512C4T polymorphism in type 2 diabetic patients and control subjects are presented in Table 2 . All genotype frequencies were in Hardy-Weinberg equilibrium. There were no significant differences in allele or genotype frequency between the groups. Although the C-allele has originally been described as the wild-type allele for this single-nucleotide polymorphism (GenBank Accession no. NM_005251), the more common allele in Scandinavian populations is T. 7, 10 Differences in type 2 diabetes-related phenotypes between genotype carriers are presented in Table 3 . Unintentionally, there were significantly more females than males homozygous for the T-allele among the control subjects (47.6 vs 35.5% for female and male control subjects, respectively, P ¼ 0.04). Consequently, all data were at least adjusted for gender and age for the subsequent analyses.
There was a significant difference in weight between carriers of different -512C4T genotypes in both type 2 diabetic patients (P a ¼ 0.04) and control subjects (P a ¼ 0.04). In the type 2 diabetic patients, this difference was significant when comparing carriers of the T-allele with subjects homozygous for the C-allele; weight 78.0 (70.0-88.0) vs 85.0 (76.2-94.5) kg (P ¼ 0.005, P a ¼ 0.01). In contrast, in the control subjects the difference was significant when comparing carriers of the T/T vs C/C and C/T genotypes; weight 72.0 (64.0-83.7) vs 76.0 (71.8-86.6) kg (P ¼ 0.06, P a ¼ 0.02). More importantly, type 2 diabetic carriers of the C/C genotype In all, 15% of the type 2 diabetic subjects received insulin treatment, 36% received oral agents (metformin or sulfonylurea), 8% received both insulin and tablets and 32% were on diet restrictions. From 9% of the patients no information about treatment was available. . The observed differences in weight and BMI were explained by an increased fat mass (Table 3) , but there were no significant differences between type 2 diabetic genotype carriers concerning either percent body fat (not shown) or distribution (WHR; Table 3 ). There was no difference in BMI between different genotype carriers among the control subjects, neither a difference in body composition, but a borderline significant increase in WHR (P ¼ 0.04, P a ¼ 0.09) that was significant when comparing carriers of the T/T vs C/C and C/T genotypes; WHR 0.86 (0.82-0.93) vs 0.90 (0.82-0.96) (P ¼ 0.02, P a ¼ 0.03). There was no significant difference in the distribution of treatments in the different -512C4T genotype groups (11% insulin, 39% oral agents, 4.5% insulin and oral agents, 36% diet restrictions and 9.5% unknown treatment among the C/C carriers vs 20% insulin, 31% oral agents, 8% insulin and oral agents, 31% diet restrictions and 10% unknown treatment among the C/T carriers vs 12% insulin, 39% oral agents, 8% insulin and oral agents, 31% diet restrictions and 10% unknown treatment among the T/T carriers, P ¼ 0.5).
FOXC2,
In light of the minor but significant association between the FOXC2 À512C4T polymorphism, body weight and BMI, we compared the upper and lower BMI quartiles of the type 2 diabetic patients as an association study for obesity. The quartiles were gender neutral, that is, composed of the upper and lower male and female BMI quartiles, respectively: 96 subjects in each quartile; BMI 24. 5 This model was also applied to data on body composition (total body fat) that were available for a subset of the study subjects (230 type 2 diabetic patients and 213 control subjects). There was a significantly increased total body fat mass in type 2 diabetic patients homozygous for À512C (P ¼ 0.04). FOXC2 À512C4T genotype was an independent predictor (P ¼ 0.002) of this variable in a multiple regression model including gender (Po0.0001) and age (P ¼ 0.3) explaining about half of the variation in body fat percent (R 2 ¼ 0.53) in type 2 diabetic patients. The model did not perform in control subjects due to skewed distribution of residuals (data not shown). There were no differences concerning metabolic parameters including insulin sensitivity and plasma lipids (Table 3) . Data are median (interquartile range). In all, 0.4 % of the genotypes (n ¼ 3) could not be obtained for technical reasons. P-values refer to ANOVA, before (P) and after (P a ) adjusting for relevant covariates (see Materials and methods for details), except for the gender comparison where they represent w 2 statistics. Duration (y), duration of type 2 diabetes at the time for phenotypic characterization. NA, not applicable. Bold indicates statistically significant.
To evaluate a putative association between FOXC2 C-512T and the dysmetabolic syndrome, we increased the number of type 2 diabetic subjects and stratified the material for a number of additional components of the syndrome: obesity, hypertension and dyslipidemia. Throughout the strata there were nonsignificant increasing and decreasing trends for the prevalence of the C-and T-alleles, respectively (P ¼ 0.4) ( Table 4 ). In males, both allele (P ¼ 0.01) and genotype (P ¼ 0.03) distributions differed significantly comparing patients with (three components) and without (none or one component) a concomitant dysmetabolic syndrome diagnosis.
Discussion
FOXC2 is a major metabolic regulator of adipocyte metabolism. It has been shown that transgenic mice overexpressing human FOXC2 in white adipose tissue exhibit enhanced insulin sensitivity and that they are relatively resistant to weight gain during high fat feeding. 6 In humans, FOXC2
mRNA levels in both visceral adipose tissue and skeletal muscle correlate with insulin sensitivity. 7 We recently identified FOXC2 as a candidate gene for insulin resistance in a study using a family-based approach: analysis of genotype discordant nondiabetic siblings with a family history of type 2 diabetes, where the C-allele of the 5 0 UTR À512C4T polymorphism was found to be associated with insulin resistance (increased HOMA-IR) and increased plasma triglyceride levels. Our findings were largely confined to female siblings. 7 In the present investigation, a case-control association study-based approach was used to study the potential role for FOXC2 in type 2 diabetes. We found no association between the FOXC2 À512C4T polymorphism and type 2 diabetes, but an association between the C-allele and obesity in type 2 diabetic subjects. Three previous studies have investigated the potential role of FOXC2 in type 2 diabetes. In agreement with our data, none of these studies performed in Japanese, 9 Pima Indians 8 and Danish Caucasians, 10 respectively, could show an association between FOXC2 and type 2 diabetes. However, also in agreement with our present data, a significant association between the À512C4T variant and BMI (P ¼ 0.03) and measures of body composition (percent body fat; P ¼ 0.02) was noted in Pima Indians. 8 Furthermore, the previously suggested gender-specific effect on triglycerides and insulin sensitivity was confirmed in the Pima Indian population, where À512C4T seems to be involved in the regulation of basal glucose turnover and plasma triglyceride levels in women. 8 Obesity, particularly abdominal obesity, usually precedes insulin resistance and type 2 diabetes 13, 18 and genetic factors are considered to explain 60% of the variance in abdominal fat. 19, 20 We found that type 2 diabetic carriers of the C/C genotype displayed an increased BMI compared to carriers of the T-allele. One should be aware of the fact that BMI and other metabolic measurements of a diabetic subject are influenced by treatment, degree of glycemic control and duration of diabetes. However, we found no significant difference in the distribution of treatments or duration of type 2 diabetes in the different genotype groups. We also found a weak association to WHR in the control subjects, but we view this association with caution since the gender distribution among the different genotype carriers in the control group was skewed and the significance of the association disappeared after adjusting for gender and age. In addition, a recent study in glucose tolerant Danish Caucasians found increased triglyceride levels (P ¼ 0.03), fasting serum C-peptide (P ¼ 0.009), insulinogenic index (P ¼ 0.04) and, restricted to females, WHR (P ¼ 0.01) in carriers of the T-allele compared to homozygous carriers of the C-allele. 10 We have no obvious explanation for this discrepancy other than methodological differences or that the polymorphism in the Danes rose on a different ancestral haplotype. This would imply that the À512C4T polymorphism is not the causal one. Although differences in gene expression due to allelic variation are relatively common in humans, 21 it must be stressed that it is presently not known whether the FOXC2 5 0 UTR polymorphism is of direct We were unable to confirm an association between the Callele of À512C4T and insulin resistance or hypertriglyceridemia in the present investigation, but we observed a significant association between FOXC2 À512C and a concomitant diagnosis of the dysmetabolic syndrome in male type 2 diabetic subjects. The gender-specific effects are more evident in females in previous reports, whereas the effect is stronger in males in this study. This is an interesting difference, but although it is conceivable that males and females react differently to environmental risk factors given the same FOXC2 genotype, we feel that it is premature to draw any conclusions from it. We cannot exclude that the differences are due to lack of power in this and previous studies. Alternative explanations such as, for example, duration at risk and gender preference in choice of treatment may also be of importance. Clearly, there is a need for larger studies addressing this issue. It should be noted that the three component dysmetabolic syndrome strata in our material do not correspond to the WHO or NCEP definitions of the syndrome as only two additional criteria in addition to type 2 diabetes are required for this diagnosis. 15 Applying these criteria, three quarters of the type 2 diabetic subjects in the present investigation have a concomitant dysmetabolic syndrome, which is in accordance with previous estimates in the Botnia study. 12 Whereas a theoretical link between FOXC2, obesity and dyslipidemia can be easily envisioned, 6, 7, 22 there is no evident functional explanation for a role for FOXC2 in hypertension, but the dysmetabolic syndrome is a complex trait and this issue certainly requires confirmation in population-based prospective studies.
In conclusion, our present data suggest that FOXC2, a key regulator of adipocyte metabolism, is weakly but consistently associated with obesity and features of the dysmetabolic syndrome, but that genetic variability in the gene does not contribute to the increased risk for type 2 diabetes.
